5‑Amino‑1MQ
Experimental metabolism-boosting compound that blocks the enzyme NNMT: switching the enzyme off sped up metabolism in mice, not studied in humans.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is 5-Amino-1MQ?
5-Amino-1MQ is an experimental compound that blocks an enzyme called NNMT, aiming to speed up metabolism. It has not been approved as a medicine anywhere, and for a few years it has been sold online as a research chemical.
In obesity, this enzyme is more active than usual in fat tissue and the liver. In mice in which the enzyme was switched off, metabolism ran faster, insulin sensitivity improved and fat cells became smaller; the compound tries to copy this effect with a drug. It has not been studied in humans, so its effects and safety are unknown. Products sold online may differ from the label and may be contaminated. It must not be used in pregnancy or breastfeeding, because nothing is known about its effects then. It is not listed separately on the anti-doping list, but the general ban on unapproved substances means it can lead to a sanction in competitive sport.
Mechanism
NNMT enzyme blocker; laboratory and animal data only
Half-life
About 4–8 hours (estimated from mice); no human measurement
Onset
In mice metabolism sped up within weeks; unknown in humans
Legal status
FDA never approved; EU EMA never approved; research-chemical underground market only. WADA NOT explicitly listed, but 'S0 catch-all non-approved substance' category may apply.
Community accounts describe 5-Amino-1MQ as highly regarded for fat loss, with users describing a subtle, background fat-loss effect that builds over time. Reports often include better day-long energy. Through NNMT inhibition, the compound lowers circulating NAD+ levels by retaining more NAD+ inside cells where it is metabolically active. It pairs well with compounds that actively boost metabolism – Cardarine, injectable L-Carnitine, or Retatrutide. Best framed as a daily background fat-loss optimizer rather than a primary driver.
5-Amino-1MQ can be administered orally (encapsulated formulations are available) or subcutaneously. If oral use causes stomach upset, taking it with food or extra water helps. Pre-cardio dosing is often considered ideal for performance applications.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Brachs S, Polack J, Brachs M, Jahn-Hofmann K, Elvert R, Pfenninger A, Bärenz F, Margerie D, Mai K, Spranger J, Kannt A . Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity.. Diabetes.
Harikrishna AS, Kesavan V . Identification of novel Piperazine based bisubstrate inhibitors of human nicotinamide N-methyltransferase (hNNMT) with potent enzyme inhibition.. Bioorg Med Chem.
Trammell SAJ, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. . Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948..
Hong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernandez-Real JM, Maratos-Flier E, Pissios P. . Nicotinamide N-methyltransferase: a methyltransferase regulating cellular metabolism through methyl donor balance. Nat Med. 2015;21(8):887-894..
Safety
Side effects, stop signs, contraindications
Side effects · 6
- No established human side-effect profile – preclinical-only NNMT inhibitor with no Phase I/II/III human trials, so the full safety window (PK, NOAEL, LD50) is unknown.
- Research-chemical sourcing risk: label-claim discrepancy and HPLC-untested content – the product may contain the wrong dose, contaminants, or a different molecule (25–30% of analogous online products did not match their label).
- Possible gastrointestinal discomfort with oral (capsule) use (nausea, stomach upset), which taking with food or more fluid may ease – not clinically validated, anecdote-level only.
- Theoretical disruption of NAD+/methyl-donor metabolism: NNMT inhibition shifts SAM-pool and cellular NAD+ balance – the long-term metabolic consequence in humans is unknown.
- Unknown hepatic and renal impact: human liver- and kidney-dependent clearance is uncharacterised, so organ burden and accumulation risk cannot be estimated (in preclinical mouse data ALT/AST did not rise significantly, but this does not extrapolate to humans).
- Unknown drug interactions: a presumed overlap exists with agents acting on NAD+/AMPK/metabolic pathways (e.g. nicotinamide riboside, metformin), but no clinical interaction data exist.
Contraindications · 6
- Pregnancy and breastfeeding – absolute contraindication (no reproductive toxicology or teratogenicity data in humans).
- Any human-consumption context in general – preclinical-only agent with no safe human protocol; intended only for in-vitro/animal research use.
- Pre-existing liver disease – relative contraindication (human hepatic clearance is unknown and the burden cannot be estimated).
- Pre-existing kidney disease – relative contraindication (human renal elimination and accumulation risk are unknown).
- Competitive athletes subject to testing – potential sanction under the WADA 'S0 non-approved substance' clause (the agent was never approved by the FDA/EMA); to be avoided.
- Minors – categorically to be avoided (no human safety data; effect on developing metabolism unknown).
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity.
Brachs S, Polack J, Brachs M, Jahn-Hofmann K, Elvert R, Pfenninger A, Bärenz F, Margerie D, Mai K, Spranger J, Kannt A
Identification of novel Piperazine based bisubstrate inhibitors of human nicotinamide N-methyltransferase (hNNMT) with potent enzyme inhibition.
Harikrishna AS, Kesavan V
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell SAJ, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al.
Nicotinamide N-methyltransferase: a methyltransferase regulating cellular metabolism through methyl donor balance
Hong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernandez-Real JM, Maratos-Flier E, Pissios P.
Telegram
Have a question about 5‑Amino‑1MQ?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.
